ID: ALA2448004

Max Phase: Preclinical

Molecular Formula: C10H14Cl3N5

Molecular Weight: 237.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cl.Cl.Clc1cn2ccnc2c(N2CCNCC2)n1

Standard InChI:  InChI=1S/C10H12ClN5.2ClH/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15;;/h3,6-7,12H,1-2,4-5H2;2*1H

Standard InChI Key:  ZAWBLLPFYFRFJG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 237.69

Molecular Weight (Monoisotopic): 237.0781

AlogP: 0.79

#Rotatable Bonds: 1

Polar Surface Area: 45.46

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.70

CX LogP: 0.53

CX LogD: -0.78

Aromatic Rings: 2

Heavy Atoms: 16

QED Weighted: 0.80

Np Likeness Score: -1.55

References

1. Lumma WC, Randall WC, Cresson EL, Huff JR, Hartman RD, Lyon TF..  (1983)  Piperazinylimidazo[1,2-a]pyrazines with selective affinity for in vitro alpha-adrenergic receptor subtypes.,  26  (3): [PMID:6298426] [10.1021/jm00357a009]

2. Meurer LC, Tolman RL, Chapin EW, Saperstein R, Vicario PP, Zrada MM, MacCoss M..  (1992)  Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.,  35  (21): [PMID:1359141] [10.1021/jm00099a012]

Source

Source(1):

• Scientific Literature